Ozempic® US approval conference call

 

Conference call following US approval of Ozempic®

On 6 December 2017 at 12.00 pm CET, corresponding to 6.00 am EST, a conference call for investors will be held.

Please use the below link to access the webcast and presentation.

- Conference call link

- Conference call presentation

If you have any questions, you are welcome to contact Novo Nordisk Investor Relations: 

+45 3075 9085              Peter Hugreffe Ankersen
+45 3079 8519              Hanna Ögren
+45 3079 4461              Anders Mikkelsen
+45 3079 3009              Christina Kjær
 +1 609 235 8567          Kasper Veje